342 related articles for article (PubMed ID: 23940108)
21. EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis.
Sen N; Cross AM; Lorenzi PL; Khan J; Gryder BE; Kim S; Caplen NJ
Mol Carcinog; 2018 Oct; 57(10):1342-1357. PubMed ID: 29873416
[TBL] [Abstract][Full Text] [Related]
22. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
Sankar S; Bell R; Stephens B; Zhuo R; Sharma S; Bearss DJ; Lessnick SL
Oncogene; 2013 Oct; 32(42):5089-100. PubMed ID: 23178492
[TBL] [Abstract][Full Text] [Related]
23. Targeted long-read sequencing of the Ewing sarcoma 6p25.1 susceptibility locus identifies germline-somatic interactions with EWSR1-FLI1 binding.
Lee OW; Rodrigues C; Lin SH; Luo W; Jones K; Brown DW; Zhou W; Karlins E; Khan SM; Baulande S; Raynal V; Surdez D; Reynaud S; Rubio RA; Zaidi S; Grossetête S; Ballet S; Lapouble E; Laurence V; Pierron G; Gaspar N; Corradini N; Marec-Bérard P; Rothman N; Dagnall CL; Burdett L; Manning M; Wyatt K; Yeager M; Chari R; Leisenring WM; Kulozik AE; Kriebel J; Meitinger T; Strauch K; Kirchner T; Dirksen U; Mirabello L; Tucker MA; Tirode F; Armstrong GT; Bhatia S; Robison LL; Yasui Y; Romero-Pérez L; Hartmann W; Metzler M; Diver WR; Lori A; Freedman ND; Hoover RN; Morton LM; Chanock SJ; Grünewald TGP; Delattre O; Machiela MJ
Am J Hum Genet; 2023 Mar; 110(3):427-441. PubMed ID: 36787739
[TBL] [Abstract][Full Text] [Related]
24. Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma.
Wang S; Huo X; Yang Y; Mo Y; Kollipara RK; Kittler R
Cancer Lett; 2023 Jan; 552():215984. PubMed ID: 36330954
[TBL] [Abstract][Full Text] [Related]
25. Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis.
Stoll G; Surdez D; Tirode F; Laud K; Barillot E; Zinovyev A; Delattre O
Nucleic Acids Res; 2013 Oct; 41(19):8853-71. PubMed ID: 23935076
[TBL] [Abstract][Full Text] [Related]
26. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
[TBL] [Abstract][Full Text] [Related]
27. EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.
Tanner JM; Bensard C; Wei P; Krah NM; Schell JC; Gardiner J; Schiffman J; Lessnick SL; Rutter J
Mol Cancer Res; 2017 Nov; 15(11):1517-1530. PubMed ID: 28720588
[TBL] [Abstract][Full Text] [Related]
28. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
[TBL] [Abstract][Full Text] [Related]
29. Ewing sarcoma with FEV gene rearrangements is a rare subset with predilection for extraskeletal locations and aggressive behavior.
Tsuda Y; Dickson BC; Swanson D; Sung YS; Zhang L; Meyers P; Healey JH; Antonescu CR
Genes Chromosomes Cancer; 2020 May; 59(5):286-294. PubMed ID: 31756779
[TBL] [Abstract][Full Text] [Related]
30. Induction of tenascin-C by tumor-specific EWS-ETS fusion genes.
Watanabe G; Nishimori H; Irifune H; Sasaki Y; Ishida S; Zembutsu H; Tanaka T; Kawaguchi S; Wada T; Hata J; Kusakabe M; Yoshida K; Nakamura Y; Tokino T
Genes Chromosomes Cancer; 2003 Mar; 36(3):224-32. PubMed ID: 12557222
[TBL] [Abstract][Full Text] [Related]
31. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite.
Grünewald TG; Bernard V; Gilardi-Hebenstreit P; Raynal V; Surdez D; Aynaud MM; Mirabeau O; Cidre-Aranaz F; Tirode F; Zaidi S; Perot G; Jonker AH; Lucchesi C; Le Deley MC; Oberlin O; Marec-Bérard P; Véron AS; Reynaud S; Lapouble E; Boeva V; Rio Frio T; Alonso J; Bhatia S; Pierron G; Cancel-Tassin G; Cussenot O; Cox DG; Morton LM; Machiela MJ; Chanock SJ; Charnay P; Delattre O
Nat Genet; 2015 Sep; 47(9):1073-8. PubMed ID: 26214589
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.
Selvanathan SP; Graham GT; Erkizan HV; Dirksen U; Natarajan TG; Dakic A; Yu S; Liu X; Paulsen MT; Ljungman ME; Wu CH; Lawlor ER; Üren A; Toretsky JA
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1307-16. PubMed ID: 25737553
[TBL] [Abstract][Full Text] [Related]
33. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
[TBL] [Abstract][Full Text] [Related]
34. Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis.
Showpnil IA; Miller KR; Taslim C; Pishas KI; Lessnick SL; Theisen ER
J Vis Exp; 2020 Jun; (160):. PubMed ID: 32658189
[TBL] [Abstract][Full Text] [Related]
35. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
36. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.
Kinsey M; Smith R; Iyer AK; McCabe ER; Lessnick SL
Cancer Res; 2009 Dec; 69(23):9047-55. PubMed ID: 19920188
[TBL] [Abstract][Full Text] [Related]
37. A Druggable Rheostat for Ewing Sarcoma?
Weiss KR; Bailey KM
Clin Cancer Res; 2022 Oct; 28(20):4360-4362. PubMed ID: 35921177
[TBL] [Abstract][Full Text] [Related]
38. AT-hook DNA-binding motif-containing protein one knockdown downregulates EWS-FLI1 transcriptional activity in Ewing's sarcoma cells.
Kitagawa T; Kobayashi D; Baron B; Okita H; Miyamoto T; Takai R; Paudel D; Ohta T; Asaoka Y; Tokunaga M; Nakagawa K; Furutani-Seiki M; Araki N; Kuramitsu Y; Kobayashi M
PLoS One; 2022; 17(10):e0269077. PubMed ID: 36194562
[TBL] [Abstract][Full Text] [Related]
39. Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription.
Patel M; Simon JM; Iglesia MD; Wu SB; McFadden AW; Lieb JD; Davis IJ
Genome Res; 2012 Feb; 22(2):259-70. PubMed ID: 22086061
[TBL] [Abstract][Full Text] [Related]
40. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.
Hahm KB; Cho K; Lee C; Im YH; Chang J; Choi SG; Sorensen PH; Thiele CJ; Kim SJ
Nat Genet; 1999 Oct; 23(2):222-7. PubMed ID: 10508522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
